Publications by authors named "R Maio"
Abnormal tau phosphorylation is a key mechanism in neurodegenerative diseases. Evidence implicates infectious agents, such as Herpes Simplex Virus 1 (HSV-1), as co-factors in the onset or the progression of neurodegenerative diseases, including Alzheimer's disease. This has led to divergence in the field regarding the contribution of viruses in the etiology of neurodegenerative diseases.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on improving the detection of KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) using a technique called ARMS-HRMA, which is more sensitive than traditional methods.
- It analyzed tumor and plasma samples from 88 newly diagnosed PDAC patients, finding G12D and G12C mutations linked to worse patient outcomes, including shorter progression-free and overall survival.
- The findings suggest ARMS-HRMA could be a quick and affordable way to help determine prognosis and treatment strategies for PDAC patients.
Objective: To assess whether the antiseizure medication levetiracetam may improve cognition in individuals with Alzheimer's disease who have not previously experienced a seizure.
Methods: We performed a randomized, double-blind, placebo-controlled crossover pilot study in individuals with mild-to-moderate Alzheimer's disease. Electroencephalography was performed at baseline and those with active epileptiform discharges were excluded.
Article Synopsis
- Scientists think that oxidative stress, which means damage from too many harmful substances in the body, is linked to Parkinson's disease (PD).
- A specific gene called LRRK2 has mutations that make it more active and can increase the risk of getting PD, and this is related to more oxidative stress.
- In studies with special lab techniques and cells from people with PD, it was found that blocking LRRK2 activity helps reduce harmful reactions, suggesting that controlling LRRK2 could help manage oxidative stress in PD.
Background: Heart failure (HF) with preserved ejection fraction (HFpEF) represents a major comorbidity in the elderly and is associated with cognitive impairment (CoI) and type 2 diabetes mellitus (T2DM). In this context, there is an increase in oxidative stress and platelet activation biomarkers. The aim of this study was to evaluate the effects of 6 months' treatment with SGLT2i on functional, mood-related, and cognitive aspects, assessed by performing a comprehensive geriatric assessment (CGA), and on oxidative stress and platelet activation biomarkers, in a cohort of HFpEF elderly patients with T2DM.
View Article and Find Full Text PDF